Jump to content

Three year genome study starts


Recommended Posts

With many drugs in prostate cancer some men respond, and some don't.

Why this is so is the big question.

Maybe the answer is in their genes, or in the genes of the prostate cancer cells.

That's what this study is trying to find out.

As men enter 4 trials of drugs researchers from this project will at the same time look at their prostate cancer genomes.

The hope is that if the genes tell us who will respond and who will not, we can check for these genes and then offer the patient drugs that work, and not subject them to drugs that will not work for them.

There is a link in the article below to the initial press release with much puff on "the dream team".

SU2C and PCF fund $10 million research study into why / how new drugs work in mCRPC

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...